NEXGEL, INC. Proceeds from Lines of Credit
NEXGEL, INC. (NXGL) reported Proceeds from Lines of Credit of $345.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-03-31
- NEXGEL, INC. proceeds from lines of credit for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- NEXGEL, INC. proceeds from lines of credit for the quarter ending 2023-12-31 was $156.00K.
- NEXGEL, INC. proceeds from lines of credit for fiscal 2024 was $345.00K, a 40.82% increase from fiscal 2023.
- NEXGEL, INC. proceeds from lines of credit for fiscal 2023 was $245.00K.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $345.00K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $345.00K 10-Q · filed 2025-11-12 | ||
| 2023-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $245.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $89.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |